Skip to main content
OpenTrials
Completed

NCT Number: NCT06592547

Intravenous Metoprolol in Septic Shock

A RCT designed to assess the effect of giving intravenous beta-blockers in patients with septic shock after achieving hemodynamic stability. The principle of this study is to control heart rate allowing for better diastolic filling and thus better perfusion.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Septic Shock Cross Infection Disease Attributes Healthcare-Associated Pneumonia Iatrogenic Disease Infections Inflammation Lung Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Ventilator-Associated Respiratory Tract Diseases Respiratory Tract Infections Sepsis Shock Shock, Septic Systemic Inflammatory Response Syndrome Ventilator Acquired Pneumonia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Alexandria Main university hospital

Alexandria, Egypt

About this study

A RCT, conducted at alexandria main university hospital, patients were divided into 2 groups, Control group which received the standard care for septic shock and metoprolol group which recieved intravenous metoprolol then patients were assessed for Blood pressure, heart rate, iv fluids needed, vasopressor doses and 28 days mortality

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The study population included adult patients (≥ 18 years) diagnosed with septic shock secondary to VAP with sinus tachycardia, from April 1, 2022, to April 31, 2023. Septic shock was defined according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). VAP was identified as per the guidelines provided by the American Thoracic Society and Infectious Diseases Society of America.

Exclusion criteria

  • Patients were excluded if they had contraindications to beta-blockers, had a history of heart failure, or had been receiving beta-blockers prior to the septic shock. Patients were also excluded if they developed complications from beta- blockers administration.

Treatment and study plan

Intravenous metoprolol tartrate

Drug

An intravenous beta-blockers, recieved FDA approval

Standard Care (in control arm)

Other

Standard care according to surviving sepsis campaign

Primary outcomes

  1. 28-day Mortality

    Time frame: 28 days

Secondary outcomes

  1. ICU stay

    Time frame: 28 days

  2. ventilator days

    Time frame: 28 days

  3. iv fluids

    Time frame: 28 days

Sponsors and collaborators

Lead sponsor

Alexandria University

Other

Registry information

Official study title

EFFECT of INTRAVENOUS METOPROLOL TARTRATE on MORTALITY in PATIENTS with SEPTIC SHOCK DUE to VENTILATOR-ASSOCIATED PNEUMONIA Thesis

Important dates

Study start
2022
Primary completion
2023
Study completion
2024
First posted
Sep 19, 2024
Registry last updated
Jan 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.